Catalog No.
PHG52001
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human MSLN (Glu296-Ser598).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
CAK1 antigen,Mesothelin,MSLN,Pre-pro-megakaryocyte-potentiating factor,MPF
Purification
Purified by antigen affinity column.
Accession
Q13421
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances., PMID:40515614
Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment., PMID:40514426
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266
[Preliminary study of mesothelin-loaded paclitaxel nanoparticles for ultrasound molecular imaging and treatment of ovarian cancer]., PMID:40375590
Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma., PMID:40362535
Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelin., PMID:40341217
Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells., PMID:40341026
Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation., PMID:40275270
Anti-Tumor Efficacy of a Mesothelin-Based Nanovaccine in a KPC Orthotopic Mouse Model of Pancreatic Cancer., PMID:40266223
Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin., PMID:40240561
Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin., PMID:40226846
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies., PMID:40132909
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager., PMID:40081946
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies., PMID:40046734
Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer., PMID:39995672
Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models., PMID:39887656
Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography., PMID:39878895
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)., PMID:39836408
A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity., PMID:39806351
Conditionally activated immunotoxins with prolonged half-life can enhance the anti-tumor activity., PMID:39603436
Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma., PMID:39542119
Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies., PMID:39431011
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors., PMID:39043602
T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin., PMID:38858494
A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin., PMID:38853444
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers., PMID:38706610
A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin., PMID:38647528
Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects., PMID:38641176
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity., PMID:38349311
Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer., PMID:38319303
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope., PMID:38227666
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation., PMID:38091375
Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents., PMID:38027361
Ex vivo pleural effusion cultures to study chimeric antigen receptor T cell cytotoxicity in an immunocompetent environment., PMID:37875122
Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate., PMID:37771390
Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer., PMID:37612388
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin., PMID:37456982
Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies., PMID:37388728
NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors., PMID:37146241
High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma., PMID:37040900
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study., PMID:36564099
Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates., PMID:36428765
Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances., PMID:35961708
Immunotherapy targeting mesothelin in acute myeloid leukemia., PMID:35946307
Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer., PMID:35925286
Construction of a 124I-Labeled Specific Antibody for the Noninvasive Detection of Mesothelin-Overexpressing Tumors., PMID:35904514
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors., PMID:35902133
A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy., PMID:35795680
Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin., PMID:35512094
Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22., PMID:35464476
For research use only. Not for human or drug use.
